Several studies have shown that immune cells express various lectin receptors, such as sialic acid-binding immunoglobulin-like lectins (SIGLECs), DC-SIGN, and MGL; these lectin receptors, after binding with tumor glycans, mediate immune suppression. Here, CD209 is linked to neoplasm.